Minocycline Treatment in Retinitis Pigmentosa

  • STATUS
    Recruiting
  • End date
    Dec 1, 2023
  • participants needed
    35
  • sponsor
    Sun Yat-sen University
Updated on 28 February 2022
minocycline
blindness
electroretinogram
retinitis
flashes

Summary

The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).

Description

Retinitis Pigmentosa (RP)is a sort of inherited blinding disorders and no effective or safe treatment are widely applied for it. The worldwide prevalence of RP is estimated to be 1/5000. RP is characterized by degeneration of peripheral rod photoreceptor(PR) and associated retinal pigment epithelium(RPE) cells. Nyctalopia and visual field constriction are common symptoms. Cone degeneration and associated loss of central vision are typically followed later.

Minocycline, a secord-generation, semi-synthetic tetracycline antibiotic, is a highly lipophilic molecule and can easily pass through the blood-brain barrier. Several animal experiments and clinical trials have reported that minocycline exert anti-apoptotic, anti-inflammatory and antioxidant effects in treating neurodegenerative diseases.

We propose to test the effect and safety of oral minocycline for retinitis pigmentosa.

Details
Condition Retinitis Pigmentosa, Inherited Retinal Dystrophy, Retina Disorder
Treatment Minocycline
Clinical Study IdentifierNCT04068207
SponsorSun Yat-sen University
Last Modified on28 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and loss of central vision; degeneration of peripheral rod photoreceptor and retinal pigment epithelium cells
Age from 18 to 60 years old
BCVA >20/100(0.2)
Full-field cone electroretinogram amplitude to 30-Hz flashes >0uV
Written informed consent is provided

Exclusion Criteria

Glucocortticoids or tetracycline were used within 3 months
Vitamin A, DHA and other neurotrophic drugs were used within 3 months
Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic retinopathy, retinal detachment
Tetracycline or minocycline allergy or intolerance
Renal or hepatic insufficiency
History of thyroid neoplasm
History of idiopathic intracranial hypertension
Pregnant or lactating females
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note